CN1929862B - 拮抗性抗-cd40单克隆抗体治疗慢性淋巴细胞性白血病的应用 - Google Patents

拮抗性抗-cd40单克隆抗体治疗慢性淋巴细胞性白血病的应用 Download PDF

Info

Publication number
CN1929862B
CN1929862B CN2004800397684A CN200480039768A CN1929862B CN 1929862 B CN1929862 B CN 1929862B CN 2004800397684 A CN2004800397684 A CN 2004800397684A CN 200480039768 A CN200480039768 A CN 200480039768A CN 1929862 B CN1929862 B CN 1929862B
Authority
CN
China
Prior art keywords
monoclonal antibody
chir
antibody
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800397684A
Other languages
English (en)
Chinese (zh)
Other versions
CN1929862A (zh
Inventor
L·隆
M·卢克曼
A·亚巴娜发
I·扎罗
S·L·奥克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyck Soma Usa Ltd
Novartis Vaccines and Diagnostics Inc
Xoma Technology Ltd USA
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN1929862A publication Critical patent/CN1929862A/zh
Application granted granted Critical
Publication of CN1929862B publication Critical patent/CN1929862B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2004800397684A 2003-11-04 2004-11-04 拮抗性抗-cd40单克隆抗体治疗慢性淋巴细胞性白血病的应用 Expired - Fee Related CN1929862B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US51733703P 2003-11-04 2003-11-04
US60/517,337 2003-11-04
US52557903P 2003-11-26 2003-11-26
US60/525,579 2003-11-26
US56571004P 2004-04-27 2004-04-27
US60/565,710 2004-04-27
US61179404P 2004-09-21 2004-09-21
US60/611,794 2004-09-21
PCT/US2004/036954 WO2005044304A2 (en) 2003-11-04 2004-11-04 Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
CN1929862A CN1929862A (zh) 2007-03-14
CN1929862B true CN1929862B (zh) 2012-02-15

Family

ID=34577850

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800397684A Expired - Fee Related CN1929862B (zh) 2003-11-04 2004-11-04 拮抗性抗-cd40单克隆抗体治疗慢性淋巴细胞性白血病的应用

Country Status (16)

Country Link
US (1) US20070110754A1 (enExample)
EP (2) EP2243491A1 (enExample)
JP (2) JP4765037B2 (enExample)
KR (1) KR20070028295A (enExample)
CN (1) CN1929862B (enExample)
AT (1) ATE474598T1 (enExample)
AU (1) AU2004287480B2 (enExample)
CA (1) CA2544364A1 (enExample)
CY (1) CY1110836T1 (enExample)
DE (1) DE602004028270D1 (enExample)
DK (1) DK1682177T3 (enExample)
IL (1) IL175393A0 (enExample)
PL (1) PL1682177T3 (enExample)
PT (1) PT1682177E (enExample)
SI (1) SI1682177T1 (enExample)
WO (1) WO2005044304A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044307A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP2248830A1 (en) * 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
DK1684805T3 (da) * 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
SI1680141T1 (sl) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
US20050281815A1 (en) * 2004-02-26 2005-12-22 Dani Eshel CD40 splice variants and their uses
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
CN101351478A (zh) * 2005-11-01 2009-01-21 诺华有限公司 抗cd40抗体的应用
JP2009517339A (ja) * 2005-11-01 2009-04-30 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
CN100503827C (zh) * 2006-03-16 2009-06-24 复旦大学 一种乙型肝炎病毒疫苗增效蛋白及其基因
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
EP2222875B1 (en) 2007-11-07 2014-08-20 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
BRPI1011394A8 (pt) 2009-04-18 2018-06-26 Genentech Inc método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
JP2016011258A (ja) * 2012-10-26 2016-01-21 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
AU2017252527A1 (en) 2016-04-18 2018-11-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
KR20210097750A (ko) * 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CN115052625B (zh) 2019-12-03 2024-11-01 埃沃特克国际有限责任公司 干扰素相关抗原结合蛋白及其用途
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
CA2184356A1 (en) 1994-03-03 1995-09-08 Russell P. Rother Terminal complement inhibitor fusion genes and proteins
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
WO2000063395A1 (en) 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
ATE541860T1 (de) * 2000-10-02 2012-02-15 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40 zur therapie von b- zell tumoren
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2005044307A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
DK1684805T3 (da) * 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
SI1680141T1 (sl) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
JP6039343B2 (ja) 2012-10-04 2016-12-07 キヤノン株式会社 電子機器、電子機器の制御方法、プログラム、記憶媒体

Also Published As

Publication number Publication date
AU2004287480B2 (en) 2011-09-15
IL175393A0 (en) 2006-09-05
HK1095269A1 (en) 2007-05-04
WO2005044304A2 (en) 2005-05-19
EP1682177A2 (en) 2006-07-26
CN1929862A (zh) 2007-03-14
PT1682177E (pt) 2010-11-29
JP2011116760A (ja) 2011-06-16
ATE474598T1 (de) 2010-08-15
WO2005044304A3 (en) 2005-08-25
EP2243491A1 (en) 2010-10-27
KR20070028295A (ko) 2007-03-12
CY1110836T1 (el) 2015-06-10
AU2004287480A1 (en) 2005-05-19
EP1682177B8 (en) 2010-09-01
CA2544364A1 (en) 2005-05-19
US20070110754A1 (en) 2007-05-17
SI1682177T1 (sl) 2010-12-31
EP1682177B1 (en) 2010-07-21
DE602004028270D1 (de) 2010-09-02
PL1682177T3 (pl) 2011-03-31
DK1682177T3 (da) 2010-11-01
JP2007510664A (ja) 2007-04-26
JP4765037B2 (ja) 2011-09-07

Similar Documents

Publication Publication Date Title
CN1929862B (zh) 拮抗性抗-cd40单克隆抗体治疗慢性淋巴细胞性白血病的应用
CN1901937B (zh) 使用拮抗性抗-cd40单克隆抗体治疗多发性骨髓瘤
CN1905897B (zh) 拮抗性抗-cd40单克隆抗体和它们的使用方法
EP1684869B1 (en) Methods of therapy for b cell-related cancers
US20080057070A1 (en) Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
CN101325970A (zh) 抗cd40抗体的应用
HK1095270B (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
HK1094162B (en) Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
HK1139964B (en) Use of antagonistic anti-cd40 monoclonal antibodies
HK1106736B (en) Combination therapy comprising anti-cd20 and anti-cd40 antibodies for the treatment of b cell-related cancers
HK1095269B (en) Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NOVARTIS VACCINES & DIAGNOSTIC

Free format text: FORMER OWNER: CHIRON CORP.

Effective date: 20080530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080530

Address after: Delaware

Applicant after: NOVARTIS VACCINES AND DIAGNOSTICS Inc.

Address before: California, USA

Applicant before: CHIRON Corp.

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: XOMA TECHNOLOGY LTD.

Free format text: FORMER OWNER: XOMA (US) LLC

Effective date: 20120213

Owner name: XOMA (US) LLC

Effective date: 20120213

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120213

Address after: Delaware

Co-patentee after: XOMA Technology Ltd.

Patentee after: NOVARTIS VACCINES AND DIAGNOSTICS Inc.

Address before: Delaware

Co-patentee before: Eyck Soma (USA) Ltd.

Patentee before: NOVARTIS VACCINES AND DIAGNOSTICS Inc.

Effective date of registration: 20120213

Address after: Delaware

Co-patentee after: Eyck Soma (USA) Ltd.

Patentee after: NOVARTIS VACCINES AND DIAGNOSTICS Inc.

Address before: Delaware

Patentee before: NOVARTIS VACCINES AND DIAGNOSTICS Inc.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120215

Termination date: 20121104